Arovella TherapeuticsASX:ALA Quick Ratio is 15.35 as of Dec. 2025, which is 495% above its 10-year median of 2.58. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Arovella Therapeutics ranks better than 87.57% on this metric.
Arovella Therapeutics has a quick ratio of 15.35. It generally indicates good short-term financial strength.
The historical rank and industry rank for Arovella Therapeutics's Quick Ratio or its related term are showing as below:
ASX:ALA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.25 Med: 2.58 Max: 15.35
Current: 15.35
During the past 13 years, Arovella Therapeutics's highest Quick Ratio was 15.35. The lowest was 0.25. And the median was 2.58.
ASX:ALA's Quick Ratio is ranked better than 87.57% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:ALA: 15.35
Arovella Therapeutics (ASX:ALA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Arovella Therapeutics Quick Ratio Related Terms
Arovella Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Arovella Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ALA vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Arovella Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arovella Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Arovella Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Arovella Therapeutics's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arovella Therapeutics (ASX:ALA) has a Quick Ratio of 15.35 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Arovella Therapeutics and its competitors. This is 495% above median its historical median of 2.58. Over the past decade, Arovella Therapeutics' Quick Ratio has ranged from 0.25 to 15.35. According to the industry distribution chart, Arovella Therapeutics ranks #176 out of 1416 companies in the Biotechnology industry, placing it in the top 12.4%.
Is Arovella Therapeutics' Quick Ratio too high?
Arovella Therapeutics' current Quick Ratio of 15.35 is 495% above median its 10-year median of 2.58. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 15.35. The Biotechnology industry median Quick Ratio is 3.60. Arovella Therapeutics' value of 15.35 is 326.4% above this industry median. Based on the distribution chart, Arovella Therapeutics ranks #176 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Arovella Therapeutics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arovella Therapeutics ranks #176 out of 1416 companies for Quick Ratio. This places Arovella Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Arovella Therapeutics' value of 15.35 is 326.4% above this benchmark. Historically, Arovella Therapeutics' own Quick Ratio has ranged from 0.25 to 15.35 over the past decade. While the company's 10-year median is 2.58 vs. the industry median of 3.60, Arovella Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arovella Therapeutics's current Quick Ratio of 15.35 is 326.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Arovella Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arovella Therapeutics's current Quick Ratio is 15.35, which is 495% above median its own 10-year median of 2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arovella Therapeutics stock overvalued right now?
Arovella Therapeutics (ASX:ALA) has a current Quick Ratio of 15.35. The current Quick Ratio is 15.35, which is 495% above median its 10-year median of 2.58 and 326.4% above the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Arovella Therapeutics (ASX:ALA), the current Quick Ratio is 15.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ALA has been successfully added to your 